论文部分内容阅读
目的探讨去整合素金属蛋白酶9(ADAM9)在乳腺癌中的表达及意义。方法采用逆转录多聚酶链聚合反应(RT-PCR)法和免疫组织化学方法检测乳腺癌组织、距离癌旁≥5cm的正常乳腺组织及腋窝淋巴结组织中ADAM9的表达,并分析ADAM9表达与乳腺癌临床病理特征之间的关系。结果 ADAM9mRNA在乳腺癌组织中的表达较正常乳腺组织(未检测到ADAM9mRNA的表达)明显增强。ADAM9蛋白表达阳性率在乳腺癌组织中明显高于正常乳腺组织(P<0.05),其在乳腺癌转移淋巴结中的表达明显高于非转移淋巴结及相应原发灶中的表达(P<0.05).乳腺癌组织中ADAM9蛋白表达阳性率与其淋巴结转移和组织学分级有关(P<0.05).结论ADAM9在乳腺癌中表达上调,可能参与了乳腺癌发生、发展过程。
Objective To investigate the expression of integrin metalloproteinase 9 (ADAM9) in breast cancer and its significance. Methods RT-PCR and immunohistochemistry were used to detect the expression of ADAM9 in breast cancer tissue, normal breast tissues ≥5cm away from cancer and axillary lymph node. The expression of ADAM9 in breast cancer Relationship between pathological features. Results The expression of ADAM9 mRNA in breast cancer tissues was significantly higher than that in normal breast tissues (no expression of ADAM9 mRNA was detected). The positive rate of ADAM9 expression in breast cancer tissues was significantly higher than that in normal breast tissues (P <0.05), and the positive rate of ADAM9 expression in breast cancer metastasis lymph nodes was significantly higher than that in non-metastatic lymph nodes and corresponding primary tumor (P <0.05) The positive rate of ADAM9 expression in breast cancer tissues was correlated with lymph node metastasis and histological grade (P <0.05) .Conclusion ADAM9 is up-regulated in breast cancer and may be involved in the development and progression of breast cancer.